MSNBC host Joy Reid slammed Supreme Court Justice Samuel Alito after the court’s provisional decision Maintain access to the mifepristone abortion pill on Friday night.
The case went to the Supreme Court after a Texas federal judge ruled April 7 that the FDA’s approval of the drug was illegal. Hours later, a judge in Washington state issued the opposite ruling, clearing the way for the Supreme Court’s decision.
On Friday they voted 7-2 to continue allowing women access to the drug, which was approved by the Food and Drug Administration more than 20 years ago and is used in more than half of all abortions in the United States. Judges Alito and Clarence Thomas dissented.
Reid, on her MSNBC show on Friday, referred to the judge as “Mullah Alito,” likening him to an Islamic extremist.
It reads to me like he’s admitting, “We don’t have an army, we don’t have the power to carry out our decisions, and we’re not sure if the government will even obey,” Reid said. This is a blatant admission of weakness and a very rude thing to note in your opposition. This man seems to feel it all in his feelings that the American people oppose his attempts to play mullah instead of Supreme Court Justice and ban abortion.
MSNBC host Joy Reid slammed Supreme Court Justice Samuel Alito after the court’s decision to temporarily maintain access to the abortion pill Mifepristone Friday night
She was specifically critical of a section of Alito’s opposition where he said “the government has not dispelled legitimate suspicions that it will obey even an unfavorable order in these cases, let alone that it will choose to take enforcement action to which it has strong objections.”
Reid had previously referred to Alito as the mullah on her Wednesday night show.
The decision came because of the April 7 ruling by Judge Matthew Kacsmarek, a Trump appointee, who found that the Food and Drug Administration had overstepped its authority when it approved the drug back in 2000.
Kacsmaryk’s order has been partially blocked by the Fifth Circuit Court of Appeals, although that court has imposed restrictions that would prevent mifepristone from being sent to patients by mail.
The Biden administration and Danco Labs, the maker of mifepristone, have warned of potential wide-ranging consequences if FDA scientists are overruled by politicians and judges.
“If allowed to take effect, lower court orders would thwart the FDA’s scientific judgment and undermine the widespread adoption in the health care system that presumes the availability of mifepristone as an alternative to surgical abortion,” Solicitor General Elizabeth Prilogar told the Supreme Court. most burdensome.” Court on file this week.
The Freedom Defense Coalition, which represents opponents of the abortion pill, faced administration concerns that amounted to “the sky is falling.”
“If this litigation concerned any other drug, there would not even be a debate as to whether this court should intervene in the middle of the course of litigation with extraordinary relief,” their attorneys wrote in a note to the court.
Reid was specifically critical of a section of Alito’s opposition stating, “The government has not allayed legitimate suspicions that it will obey even an unfavorable order in these cases, much less that it will choose to take executive action to which it has strong objections.”
The case has divided the nation, with more than 150 Republican lawmakers backing the conservative plaintiffs.
On the other hand, Democrats and leading medical societies have pushed for the continued availability of mifepristone.
The original stay expired on Wednesday but Judge Samuel Alito extended it until midnight on Friday.
The justices met for a special conference on Friday, where they can talk about the case.
The challenge to mifepristone, which opponents of abortion present, is the first abortion Controversial access to the nation’s highest court since its conservative majority overturned a law ruling against Wade 10 months ago.
Since then, more than a dozen countries have banned abortion completely and several others have imposed severe restrictions.
Staff of the group, Progressive Anti-Abortion Rising Christine Turner, of San Francisco, left, Lauren Handy, of Washington, and Carolyn Smith, of Washington, right, demonstrate against the abortion pill outside the Supreme Court
A new CBS News poll last week found that nearly two-thirds of the country’s population want mifepristone to remain available amid the fierce debate over abortions that are taking place across the country.
Abortion rights are expected to be one of the dominant issues in the 2024 presidential election.
In Texas, abortion opponents sued in November, arguing that the Food and Drug Administration’s original approval of mifepristone 23 years ago and subsequent changes were flawed.
They won a ruling on April 7th US District Judge Matthew KacsmarekTrump, appointed by former President Donald Trump, to revoke the Food and Drug Administration’s approval of mifepristone. The judge gave the Biden administration and New York-based Danco Laboratories, which makes mifepristone, a week to appeal and seek to keep its ruling pending.
In response to a speedy appeal, two Trump appointees to the Fifth Circuit to the US Court of Appeals said The original FDA approval will remain in effect for the time being.
But Justices Andrew Oldham and Kurt Englehart said most of the remaining provisions in Kaksmarek’s ruling could become effective by the time the case is decided in federal courts.
Their ruling would overturn changes made by the FDA from 2016, including extending the gestational age from seven to 10 weeks when mifepristone can be used safely.
The court also said that the drug cannot be mailed or dispensed as a generic drug and that patients who seek it need to have three in-person visits with a doctor. Women may also be required to take higher doses of the drug than the FDA says is necessary.
Management and Danco He said that chaos would ensue if these restrictions came into effect while the case was in progress. Adding to the potential confusion, a federal judge in Washington ordered the FDA to maintain access to mifepristone under existing rules in 17 Democratic-led states and the District of Columbia that filed a separate lawsuit.
Medical groups report that mifepristone has been used by millions of women over the past 23 years with a low complication rate.
Common side effects of medications with mifepristone include cramping, bleeding, nausea, headache, and diarrhea.
In rare cases, women can experience excessive bleeding that requires surgery to stop it.
Mifepristone is the first abortion case heard by the nine justices since the conservative majority overturned Roe v. Wade
More than 5.6 million women in the United States had used the drug as of June 2022, according to the Food and Drug Administration.
In that period, the agency received 4,200 reports of complications in women, or less than a tenth of 1% of women who took the drug.
Currently, the Supreme Court is only required to block lower court decisions until the end of the legal case.
But management and Danco have a backup argument if the court disagrees.
They are asking the court to accept the challenge to mifepristone, hear the arguments and decide the case by early summer.
The court rarely takes such a step before at least one appeals court has carefully examined the legal issues involved.
The New Orleans-based Fifth Circuit has already ordered a fast-track schedule for hearing the case, with arguments set for May 17.